Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VCN-01,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Theriva Biologics
Deal Size : $4.7 million
Deal Type : Acquisition
Synthetic Biologics Completes Acquisition of VCN Biosciences
Details : The acquisition transforms Synthetic Biologics’ pipeline with the addition of VCN's lead clinical-stage drug candidate, VCN-01, as well as preclinical stage VCN-11, both of which are next-generation OVs in development for the treatment of cancers with ...
Product Name : VCN-01
Product Type : Microorganism
Upfront Cash : Undisclosed
November 03, 2022
Lead Product(s) : VCN-01,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Theriva Biologics
Deal Size : $4.7 million
Deal Type : Acquisition
Details : VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma.
Product Name : VCN-01
Product Type : Microorganism
Upfront Cash : Inapplicable
August 02, 2022
Lead Product(s) : VCN-01,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Grifols International
Deal Size : $77.4 million
Deal Type : Acquisition
Details : VCN has the rights to four exclusive patents for proprietary technologies, including VCN-01, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional pat...
Product Name : VCN-01
Product Type : Microorganism
Upfront Cash : $4.7 million
December 14, 2021
Lead Product(s) : VCN-01,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Grifols International
Deal Size : $77.4 million
Deal Type : Acquisition
Reset All
